• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

June 30, 2014

View Archived Issues

Index to double down on Kappaproct after mixed phase III data in ulcerative colitis

As is so often the case with gastrointestinal disease, Index Pharmaceuticals AB obtained phase III results with its topical ulcerative colitis drug Kappaproct that were neither black nor white but a distinct shade of gray. Read More

Mannkind's Afrezza passes FDA; next test: Commercialization

On its third try before the FDA, Mannkind Corp.'s inhaled insulin Afrezza (insulin human [rDNA origin]) finally won approval Friday, capping nearly eight years of dogged pursuit in the wake of the spectacular commercial failure of first-generation inhaled insulin Exubera, but an FDA nod is only the first battle; the Valencia, Calif.-based firm still faces challenges of proving the drug's worth in the marketplace. Read More

Biosimilars makers seek to defray U.S. risks

SAN DIEGO – With an untested approval pathway for biosimilars in the U.S., industry intellectual property experts well versed in the world of small-molecule generics told BIO 2014 attendees that the best path for bringing follow-on biologics to market remains muddy. Read More

Bird's-eye view of cost of cancer therapies may shortchange patients

SAN DIEGO – What's the value equation for the cost of cancer therapy, and what portion of that cost should public and private payers bear? The topic – an important one for patients and drug developers alike – was the intriguing premise of a session on the final day of the BIO International Convention. Read More

Dead cat bounces? Upswing, creativity strong in new data

SAN DIEGO – The U.S. tops most lists in biotech, but studying data from other international players can provide lessons for the front-runner and everyone else. Such intent is motivating Scientific American Worldview, in its sixth year of rankings that were detailed during a session on the final day of the BIO International Convention. Read More

Pushing stem cells toward a higher pluripotency

HONG KONG – Researchers from the Riken Center for Life Science Technologies in Japan said they have gained new insights into the role of a chemokine protein in the enhancement of stem cell pluripotency, an improved understanding that could lead to the development of more stable and clinically useful stem cells. Read More

Study: Aligning EMA, HTA facilitates process, but clarity needed

LONDON – The EMA published the conclusions of a first attempt to bring its pan-European assessments of absolute efficacy into line with the needs of national health technology assessment (HTA) bodies that are responsible for making judgements on relative efficacy of drugs, to feed into reimbursement decisions at a member state level. Read More

Financings

Karyopharm Therapeutics Inc., of Natick, Mass., priced its public offering of about 2.6 million shares at $42.50 apiece, a slight discount to Thursday's closing price. Read More

Stock movers

Read More

Other news to note

Gilead Sciences Inc., of Foster City, Calif., said it submitted a new drug application to Japan's Pharmaceutical and Medical Devices Agency for approval of sofosbuvir, a once-daily nucleotide analogue polymerase inhibitor, for the treatment of chronic hepatitis C virus (HCV) infection. Read More

In the clinic

Essentialis Inc., of Carlsbad, Calif., said it dosed the first patient in study PC025, which is designed to evaluate the safety and efficacy of diazoxide choline controlled-release (DCCR) tablets in obese Prader-Willi syndrome (PWS) patients. Read More

Pharma: Other news to note

Eli Lilly and Co., of Indianapolis, and Boehringer Ingelheim GmbH, of Ingelheim, Germany, said the Committee for Medicinal Products for Human Use issued a positive opinion recommending approval of LY2963016, an insulin glargine product. Read More

Bench Press: BioWorld looks at translational medicine

Researchers from the Israeli Hebrew University have gained new insights into one way in which bacteria learn to live with antibiotics. Resistance is the ability to survive antibiotic treatment, as long as the concentrations of antibiotics are not too high. Read More

Icon Bioscience enrolls pivotal ph III early for cataract surgery-related inflammation

Icon Bioscience Inc. has kept development of its pipeline of drugs targeting ophthalmic indications largely under wraps. That posture may change as lead candidate IBI-10090, designed to treat inflammation associated with cataract surgery, moves through a pivotal phase III trial that completed enrollment four months ahead of schedule. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 10, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 10, 2025.
  • Neuronata-R

    Corestemchemon preps US BLA filing for stem cell ALS therapy

    BioWorld
    Corestemchemon Inc. is planning to file a BLA for Neuronata-R (lenzumestrocel) by the end of 2025 to gain accelerated approval from the U.S. FDA, company...
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Enflonsia

    Merck wins approval FDA in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (cesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe